



## Patterns of engagement in care across the cyclical HIV cascade: Insights for the CQUIN Network

#### August 6, 2024

HIV Coverage, Quality, and Impact Network



## Welcome/ Bienvenue



**Bill Reidy** Deputy Director, Strategic Information ICAP at Columbia University

- Be sure you have selected the language of your choice using the "Interpretation" menu on the bottom of your screen.
- Assurez-vous d'avoir sélectionné la langue de votre choix à l'aide du menu <<Interprétation>> en bas de votre écran Zoom.



#### Housekeeping

- 60-minute webinar with two presentations followed by a brief Q&A
- Slides and recording will be available on the CQUIN website (www.cquin.icap.columbia.edu)
- Please type questions in the Q&A box located on the toolbar at the bottom of your screen
- If you would prefer to speak, please use the "raise hand" function on the toolbar and we will unmute you so that you have control of your microphone
- If you are a French or English speaker, please ask your question in your language of choice and the interpreters will translate as needed





#### Agenda

- **1. Welcome and Introductions**: Bill Reidy, Deputy Director, Strategic Information, ICAP/CQUIN
- 2. Presentation 1: How person-centred data could improve the accuracy of HIV care cascade reporting : David Etoori, Research Fellow University College, London Institute for Global Health
- Presentation 2: Using routine health data to explore patterns of patient engagement with antiretroviral care: Claire Keene, PhD Student, University of Oxford
- 4. Q&A Discussion: Bill Reidy, ICAP/CQUIN (Moderator)
- 5. Closing Remarks



#### Supporting re-engagement in HIV treatment services



Policy brief



#### Key messages

People who have been diagnosed with HIV may disengage from care after starting antiretroviral therapy (ART) and may do so more than once.

- Individuals with interrupted HIV care and treatment may reengage to care with advanced HIV disease and a range of clinical, psychosocial and service delivery needs.
- WHO recommends tracing people who have disengaged from care and providing support for re-engagement back in care, including adherence support and differentiated service delivery for HIV treatment to reduce the risk of future disengagement.
- Health-care providers must refrain from punitive actions and ensure a welcoming, non-stigmatizing environment and equitable access to services.
- Programmes should engage communities at different levels to ensure effective re-engagement strategies tailored to clients' needs.
- When differentiated service delivery pathways are designed at reengagement, factors such as the clinical profile, the diverse needs and reasons for disengagement and specific population needs should be considered; person-centred solutions should be explored.
- How engagement in care and treatment is supported and measured urgently needs to be improved, including close monitoring of treatment adherence and viral suppression and identifying and responding to inconsistent patterns of retention in care.



Sustained engagement in HIV care and treatment is critical to achieving sustained undetectable viral load and optimal clinical and public health outcomes. David Etoori Research Fellow, University College London Institute for Global Health, UK









## How person-centred data could improve the accuracy of HIV care cascade reporting

Dr David Etoori

HIV Coverage, Quality, and Impact Network



## Background:

- Changes in the aims of national treatment programmes
- Changes in the treatment cohorts of these programmes
  - Healthier individuals initiating antiretroviral therapy (ART)
  - Loss to follow-up no longer synonymous with mortality
  - Increasing instances of re-engagement in care



Ehrenkranz P, Rosen S, Boulle A, Eaton JW, Ford N, Fox MP, et al. (2021) The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals. PLoS Med 18(5): e1003651.

## Background

#### Misreporting of Patient Outcomes in the South African National HIV Treatment Database: Consequences for Programme Planning, Monitoring, and Evaluation

David Etoori<sup>1\*</sup>, Alison Wringe<sup>1</sup>, Chodziwadziwa Whiteson Kabudula<sup>2</sup>, Jenny Renju<sup>1,3</sup>, Brian Rice<sup>4</sup>, F. Xavier Gomez-Olive<sup>2</sup> and Georges Reniers<sup>1,2</sup>

#### RESEARCH ARTICLE

Investigating clinic transfers among HIV patients considered lost to follow-up to improve understanding of the HIV care cascade: Findings from a cohort study in rural north-eastern South Africa

David Etoori<sup>1\*</sup>, Chodziwadziwa Whiteson Kabudula<sup>2</sup>, Alison Wringe<sup>1</sup>, Brian Rice<sup>1</sup>, Jenny Renju<sup>1,3</sup>, Francesc Xavier Gomez-Olive<sup>2</sup>, Georges Reniers<sup>1,2</sup>

#### Outcomes After Being Lost to Follow-up Differ for Pregnant and Postpartum Women When Compared With the General HIV Treatment Population in Rural South Africa

David Etoori, MPH,<sup>a</sup> Francesc Xavier Gomez-Olive, PhD,<sup>b</sup> Georges Reniers, PhD,<sup>a,b</sup> Brian Rice, PhD,<sup>c</sup> Jenny Renju, PhD,<sup>a,d</sup> Chodziwadziwa W. Kabudula, PhD,<sup>b</sup> and Alison Wringe, PhD<sup>a</sup>

#### RESEARCH

#### **Open Access**

#### Patterns of engagement in HIV care during pregnancy and breastfeeding: findings from a cohort study in North-Eastern South Africa

David Etoori<sup>1\*</sup>, Brian Rice<sup>2</sup>, Georges Reniers<sup>1,3</sup>, Francesc Xavier Gomez-Olive<sup>3</sup>, Jenny Renju<sup>1,4</sup>, Chodziwadziwa Whiteson Kabudula<sup>3</sup> and Alison Wringe<sup>1</sup>



## **Background: Inspiration**

- Work with Prof. Maya Petersen back in 2013
- MACH14: A Multi-Site Collaboration on ART Adherence Among 14 Institutions
  - Use electronic Medical Event Monitoring System
     (MEMS) to measure adherence





# Research paper

Etoori D, Wringe A, Reniers G, Gomez-Olive FX, Rice B (2024) Moving towards a person-centred HIV care cascade: An exploration of potential biases and errors in routine data in South Africa. PLOS Glob Public Health 4(6): e0002509. RESEARCH ARTICLE

## Moving towards a person-centred HIV care cascade: An exploration of potential biases and errors in routine data in South Africa

David Etoori<sup>1\*</sup>, Alison Wringe<sup>2</sup>, Georges Reniers<sup>2,3</sup>, Francesc Xavier Gomez-Olive<sup>3</sup>, Brian Rice<sup>2,4</sup>

 University College London, London, United Kingdom, 2 London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 MRC/WITS Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, University of Witwatersrand, Johannesburg, South Africa, 4 University of Sheffield, School of Health and Related Research, Sheffield, United Kingdom

## Methods: Setting & Data

Agincourt Health and Demographic surveillance system



## Methods: Building sequences & cluster analysis



HIV positive not on ART

|--|

Transferred

ART



Late for an appointment



Re-engaged

- Clinics typically run 28-day refill schedules
- Assume treatment taken as prescribed
- Identified care pathway clusters using Optimal Matching
  - Identified factors associated with cluster membership



## **Results:**

5084 patient records linked to 4947 unique individuals

 134 individuals linked to multiple records 133 total transfers

106 (79.7%)
 undocumented

93 of 4947 [1.9% (95% C.I: 1.5-23)] had multiple HIV tests

 Repeat testing associated with undocumented transfers

## Results: Engagement clusters

- 2,666 (53.9%) late ART, unstable engagement
- 679 (13.7%) early ART, prolonged disengagement
  - Younger, PMTCT, Males
- 1,602 (32.4%) early ART, stable engagement
  - Older, ART before 'treat all'



## **Case studies**



Clinic 2 Clinic 3

4517

3858

3091

025

0

10 seq. (n=4947) 3508

## Implications

- Cyclical engagement patterns (2/3) more common than traditional linear patterns (1/3)
  - Movement between periods of engagement and disengagement
- Undocumented transfers associated with
  - Loss to follow-up
  - Repeat testing
  - Double counting of individuals



## Conclusions

- Aggregate data lacks the nuance necessary for accurately reporting 95-95-95 goals
- As treatment cohorts become healthier, treatment programmes will require more robust cascades
  - Able to follow an individual across their treatment journey
  - Account for movement between clinics and regions



#### Acknowledgements

LONDON SCHOOL of HYGIENE &TROPICAL MEDICINE

- Dr. Alison Wringe
- Dr. Georges Reniers
- Dr. Brian Rice
- Dr. Francesc X. Gomez-Olive
- Dr. Chodziwadziwa Kabudula





MeSH Consortium

Measurement & Surveillance of HIV Epidemics







Thank you!



Claire Keene PhD Student University of Oxford









Dr Claire Keene

Insights for the CQUIN Network

6<sup>th</sup> August 2024



## Monitoring the HIV epidemic



Ehrenkranz P, Rosen S, Boulle A, Eaton JW, Ford N, Fox MP, et al. The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals. PLoS Med [Internet]. 2021;18(5):1–10. Available from: http://dx.doi.org/10.1371/journal.pmed.1003651 Euvrard J, Timmerman V, Keene CM, Phelanyane F, Heekes A, Rice BD, Grimsrud A, Ehrenkranz P, Boulle A. The cyclical cascade of HIV care: Temporal care engagement trends within a population-wide cohort. PLoS Med. 2024 May 10;21(5):e1004407. doi: 10.1371/journal.pmed.1004407

# Exploring churning and patterns of engagement over time

#### Context: Khayelitsha and Gugulethu



Provincial Health Data Centre (PHDC)



Boulle A, Heekes A, N T, et al. Data Centre Profile : The Provincial Health Data Centre of the Western Cape. Int J Popul Data Sci. 2019;4(2):06. doi:https://doi.org/10.23889/ijpds.v4i2.1143 / Graphic taken from a presentation by Andrew Boulle at Open HIE 2018: Where there is no EMR - Functional health information exchange in poorer countries – South African experience

## Khayelitsha and Gugulethu Cohort

Drainage Distribution



-

\_

-

-

Male 31% Khayelitsha Female 69% Median age at ART start: 31 years (26-38)Age at ART Start Follow up time (median [IQR]) 4 years (2.75-5.08) Proportion with  $\geq$  60 months follow-up 26422 (38%)

Sex Distribution

## 95-95-95 Cascade

On HIV treatment Virally surpressed

#### Treatment success 84% of those on treatment with a VL (50% of cohort)

Access

**53%** of those alive at database closure (30<sup>th</sup> September 2022)





#### **Treatment interruptions:** >90 days late for an expected visit



#### Recurrent treatment interruptions



#### Hazard highest in 1<sup>st</sup> year after ART start/ restart

#### Hazard function of time to 1<sup>st</sup> treatment interruption



#### Hazard function of time to subsequent interruptions

### Return to HIV care



#### Why does it matter?

Poor retention driving gaps in 95-95-95

- Treatment interruptions are common
- Lead to poor viral suppression

How do we structure the **health** system to encourage people to engage with care long term with limited resources?

#### Associations with interruptions: Cox Regression

|                  |  | adjHR (95% CI)   | p value                       |
|------------------|--|--|-------------------------------|
| Domographics     | Youth <25 at ART initiation  | 1.25 [1.22-1.28]   | <0.0001                       |
| Demographics     | Male sex   | 1.20 [1.18-1.23]   | <0.0001                       |
|                  | Comorbidity at ART initiation  | 0.79 [0.76-0.82)   | <0.0001                       |
|                  | Comorbidity diagnosed while on ART   | 0.66 [0.64-0.69)   | <0.0001                       |
| Clinical history | <ul> <li>Pivotal event at ART initiation</li> <li>Effect of pivotal event at initiation in the first 180 days</li> <li>Effect of pivotal event at initiation after 180 days</li> </ul> | 0.76 [0.70-0.81]<br>1.41 [1.37-1.46]                     | <0.0001<br><0.0001            |
|                  | Has pivotal while on ART   | 1.22 [1.19-1.25]   | <0.0001                       |
|                  | ART initiation year  | 0.86 [0.85-0.87]   | <0.0001                       |
| HIV history      | <ul> <li>CD4 at ART initiation (ref CD4 &gt;200)</li> <li>Advanced HIV Disease (CD4 ≤200)</li> <li>No CD4 at baseline</li> </ul>   | 0.93 [0.91-0.96]<br>1.27 [1.25-1.30]                     | <0.0001<br><0.0001            |
| The firstory     | Regimen at ART initiation (ref NNRTI-based)         -       PI-based         -       INSTI-based         -       Unknown   | 1.61 [1.48-1.75]<br>0.91 [0.88-0.94]<br>1.43 [1.35-1.52] | <0.0001<br><0.0001<br><0.0001 |
| World events     | Has follow-up time during the pandemic   | 1.76 [1.72-1.81]   | <0.0001                       |

#### Gap vs no gap

• Subtle differences

#### Those out of care are:

- Younger
- Have lower rates of NCDs
- More likely to be pregnant, have TB or be admitted at ART initiation or while on ART
- Longer ART duration/ follow-up time
- Fewer on DTG at ART start

#### Mostly similar

• Most middle-aged women with no chronic disease or pivotal event, on an NNRTI regimen at initiation

| Characteristic                                | Never had an interruption | Had an interruption |
|---|---------------------------|---------------------|
| Demographics                                  |                           |                     |
| Number (n[%])                                 | 23578 [34%]               | 45310 [66%]         |
| Age at ART initiation (median [IQR] in vears) | 33 [27-41]                | 30 [25-37]          |
| Clinical history                              |                           |                     |
| Chronic disease diagnoses (n [%]):            |                           |                     |
| ~ Hypertension                                | 4376 [19%]                | 4657 [10%]          |
| ~ Diabetes                                    | 1222 [5%]                 | 1308 [2.9%]         |
| Mental health diagnosis                       | 1147 [4.9%]               | 2266 [5%]           |
| Pivotal events (n [%]):                       |                           |                     |
| ~ Pregnancy as a proportion of females        | 6165 [37%]                | 13907 [45%]         |
| ~ Tuberculosis                                | 3874 [16%]                | 8705 [19%]          |
| Hospital admission                            | 5363 [23%]                | 11472 [25%]         |
| ~ COVID-19 diagnosis                          | 1095 [4.6%]               | 1690 [3.7%]         |
| HIV history                                   |                           |                     |
| ART duration at censoring(median [IQR]        | 3.58 [2.17-4.84]          | 4.18 [3.01-5.18]    |
| in years)                                     | <                         |                     |
| ART initiation year (median [IQR])            | 2019 [2017-2020]          | 2018 [2017-2019]    |
| Regimen at ART initiation (n [%])             |                           |                     |
| ~ NNRTI-based                                 | 16959 [72%]               | 36955 [82%]         |
| ~ PI-based                                    | 134 [0.6%]                | 656 [1.4%]          |
| ~ INSTI-based                                 | 6189 [26%]                | 6326 [14%]          |
| ~ Unknown                                     | 296 [1.3%]                | 1373 [3.0%]         |

# Other ways to stratify the population?

## Different approaches



Mody A, Eshun-Wilson I, Sikombe K, et al. Longitudinal engagement trajectories and risk of death among new ART starters in Zambia: A group-based multi-trajectory analysis. *PLoS Med*. 2019;16(10):1-25. doi:10.1371/journal.pmed.1002959 Keene et al. Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks. *JAIDS*. 2023; 92(5): 422-429. DOI: 10.1097/QAI.000000000003157

#### How does this relate to precision public health?

**GROUP-BASED** 

#### **Population level**





Ideal



Mody A, Eshun-Wilson I, Sikombe K, et al. Longitudinal engagement trajectories and risk of death among new AKI starters in Zampia: A group-based multi-trajectory analysis. *PLOS INER.* 2019;16(10):1-25. doi:10.1371/journal.pmed.1002959 Keene et al. Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks. *JAIDS.* 2023; 92(5): 422-429. DOI: 10.1097/QAI.00000000003157

## Subgroups of retention in care (treatment interruptions)

#### 5 groups

- 1. Optimal engagement
- 2. Early disengagement and return
- 3. Early disengagement and delayed return
- 4. Delayed disengagement
- 5. Early disengagement



Time since ART initiation (months)

#### Options

- Return..
- Died
- Moved and re-engaged elsewhere

#### Some caveats to using routine data

## Fill the gap Actual patient in More extensive data linkage their day-to-day life New analytic methods Collecting more data Health system's view of the patient from intermittent interactions

•

•

٠



## Insights

- Retention is the bottleneck to achieve population-level viral suppression
- Treatment interruptions are common
  - Nearly universal given sufficient follow-up time
  - Normal part of a lifetime relationship with ART?
- Most return to care
  - Similar patterns after initiation and restart
  - But worse outcomes with a history of nonretention
- Engagement is not binary
  - Disengagement is heterogenous
  - Difficult to predict (with routine data)

## $\rightarrow$ $\rightarrow$ Precision public health

#### approach

- Target interventions to subgroups of similar engagement behaviour?
- Behavioural subgroups capture some of the heterogeneity
- Need to understand what determines different trajectories
  - (its not demographics)

## Thanks

- Provincial Health Data Centre and team
- Supervisors: Prof Catherine Orrell, Dr Jake McKnight and Prof Mike English
- Jonathan Euvrard
- Tali Cassidy
- Scott Colwell and Aaloke Mody
- All the people who have given me input
  - CoCT
  - Health Systems Collaborative Team
  - Palindrome
  - PHDC
  - Stats Coven at Primary Care, University of Oxford
  - Thesis Committee: Adrian Smith, Neo Tapela, and Jason Oke







Register interest: MSc Health Service Improvement and Evaluation (HSIE)











Thank you!



## **Q&A** Discussion



**David Etoori** Research Fellow, University College London Institute for Global Health, UK



**Claire Keene** PhD Student University of Oxford, UK



The HIV Learning Network for Differentiated Service Delivery





Slides & recordings from this session are available on the CQUIN Website https://cquin.icap.columbia.edu

> The <u>next</u> webinar will be held on September 3: Client Satisfaction

HIV Coverage, Quality, and Impact Network

